Company: NDRA
Filing Date: 2025-10-30
Form Type: 424B5
Source: 0001213900-25-103705
Chunk: 5

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-10-30
Form: 424B5
Chunk 5
---
 of forward-looking statements include, among others, statements we make regarding: estimates of the timing of future events and anticipated results of our development efforts, including the timing of submission for and receipt of required regulatory approvals and product launches; statements relating to future financial position and projected costs and revenue; expectations concerning our business strategy; and statements regarding our ability to find and maintain development partners. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside our control. Our actual results and financial condition may differ materially from those in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following:

| ● | our limited commercial experience, limited cash and history of losses; |

| ● | our ability to obtain adequate financing to fund our business operations in the future; |

| ● | our ability to achieve profitability; |

| ● | delays and changes in regulatory requirements, policy and guidelines, including potential delays in submitting required regulatory 
 applications or other submissions with respect to U.S. Food and Drug Administration (“FDA”) or other regulatory agency approval;   |

| ● | our ability to obtain CE mark certification and secure required FDA and other governmental approvals for our Thermo-Acoustic Enhanced 
 Ultrasound (“TAEUS”) applications                                                                                                     |

| ● | our ability to develop a commercially feasible application based on our TAEUS technology; |

| ● | market acceptance of our technology; |

| ● | the effect of macroeconomic conditions on our business; |

| ● | results of our human studies, which may be negative or inconclusive; |

<div align='center'>S-2</div>

| ● | our ability to find and maintain development partners; |

| ● | our reliance on third parties, collaborations, strategic alliances and licensing arrangements to complete our business strategy; |

| ● | the amount and nature of competition in our industry; |

| ● | our ability to protect our intellectual property; |

| ● | potential changes in the healthcare industry or third-party reimbursement practices; |

| ● | our ability to